




Lo último en *hematología* para *farmacia hospitalaria*

GemPhasis



Con el patrocinio de:
REGENERON*



Lo último en *hematología* para *farmacia hospitalaria*

eMPhasis

Jueves 11/06/2026

M^a Estela Moreno

Serv Farmacia, Hospital de la Santa Creu I Sant Pau

Presentación Guías de Tratamiento

- Leucemia Linfocítica Crónica
- Linfoma de Hodgkin
 - Pendiente publicación Hemasphere 2026
 - Actualización diagnóstico, tratamiento, seguimiento
 - Primera línea enfermedad avanzada:
 - Brentuximab vedotina
 - Inhibidores punto control inmunitario
 - Recaída/refractarios
 - Inhibidores punto control inmunitario

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation

Barbara Eichhorst^{1,^}  | Paolo Ghia^{2,3,^}  | Francesc Bosch⁴ | Ruth Clifford^{5,6} | Michael Gregor⁷ | Romain Guieze⁸ | Arnon P. Kater⁹  | Carsten U. Niemann¹⁰ | Sarka Pospisilova¹¹ | Tadeusz Robak¹² | Anna Schuh¹³ | Kostas Stamatopoulos¹⁴ | Tamar Tadmor¹⁵ | Nick York¹⁶

Correspondence: Barbara Eichhorst (barbara.eichhorst@uk-koeln.de) and Paolo Ghia (ghia.paolo@hsr.it)

Abstract

Previous editions of the European guidelines for the management of chronic lymphocytic leukemia (CLL) were developed by experts in CLL under the auspices of the European Society for Medical Oncology (ESMO). These previous editions have served as a reference text for many physicians caring for patients with CLL. The current, 2026 edition, represents the new, updated guidelines that, for the first time (and in agreement with ESMO), were written on behalf of the European Hematology Association (EHA), which will be solely responsible for subsequent editions, published annually to keep pace of the fast-moving field of CLL research and clinical applications. The new guidelines support approaching the management of CLL in a more holistic fashion, from the initial diagnosis (including active surveillance) to treatment need, with particular emphasis on the interplay between disease- and patient-specific criteria for decision-making, to the latest stage of possible Richter transformation, which is now specifically mentioned in the title of the guidelines. These new recommendations are the result of a consensus reached among medical experts from several European countries and, for the first time, have involved patient advocacy representatives, which is in line with EHA standard operating procedures for clinical practice guideline development. Updates in terms of treatment options include the recently European Medicines Agency-approved, time-limited combination therapy acalabrutinib and venetoclax ± obinutuzumab as first-line treatment, and continuous pirtobrutinib for patients exposed to covalent Bruton's tyrosine kinase inhibitors in the relapsed/refractory setting.

Ritmo circadiano y hematología

- Conexión entre el ritmo circadiano, el sistema nervioso y la regulación de las células madre hematopoyéticas. Cronobiología
- Importancia del estilo de vida
 - Falta de sueño o interrupciones/fragmentación del sueño
 - Acelera expansión de clones mutadas
 - Estado proinflamatorio
 - Ejercicio físico
 - Factor protector
 - Papel en los resultados del TPH y EICR
- Modulación colinérgica de los linfocitos
 - Sinergias en EICH
 - Papel en la aferesis y posterior expansión y actividad de las células CAR-T
- Cronoterapia para optimizar la administración de fármacos contra la leucemia

Claire Harrison – EHA Lifetime Achievement Award

Notes to my younger self



Be **brave** enough to start, even when you don't know where the journey will lead.



Build **communities**, not projects.



Listen to patients. They will teach you more than you can imagine.



Find great **people**, trust them, and help them shine.



Collaboration will achieve more than determination alone.



Progress is rarely quick. Be **patient** and keep going.



Celebrate the **friendships** you make along the way.



Remember that lasting change is always a **team effort**.

